Post-translational modification: Phosphorylation of the PPPSP motif creates an inducible docking site for Axin. Palmitoylation is required for LRP6 to exit the endoplasmic reticulum (ER).
Localisation
Membrane; single-pass type I membrane protein.
Function
Involved in the Wnt/beta catenin signaling pathway, acting as a co-receptor together with Frizzled for Wnt ligands.
Mutations

Germinal
The heterozygous LRP5 V171 mutation cosegregated with high bone density. This gain-of-function mutation in LRP5 causes an autosomal dominant disorder characterized by high bone density, torus palatinus, and a wide, deep mandible. In 2001, Gong et al. reported that they identified a total of six different homozygous frame-shift or nonsense mutations in affected offspring from consanguineous families affected by osteoporosis pseudoglioma syndrome. They also found homozygous missense mutations in affected patients from two other consanguineous families and heterozygous nonsense, frame-shift, and missense mutations in affected patients from four nonconsanguineous families. Many patients with this syndrome are also born with severe disruption of the ocular structure, phthisis bulbi. Jiao et al. reported that homozygous mutations R570Q, R752G, and E1367K in LRP5 cosegregated with familial exudative vitreoretinopathy (FEVR). There are many other papers reporting LRP5 gene mutations and SNP polymorphisms that are associated with bone density variation, familial exudative vitreoretinopathy, obesity, etc.
Somatic
Westin's group reported that the tumor-associated shorter transcript of LRP5 containing an in-frame deletion of 142 amino acids (D666-809) was strongly implicated in deregulated activation of the Wnt/betacatenin signaling pathway in hyperparathyroid tumors and mammary gland tumorigenesis.
Schematic representation of LRP5 mutations; those associated with osteoporosis pseudoglioma (OPPG) syndrome, autosomal-dominant familial exudative vitreoretinopathy (FEVR), and various high-bone-density diseases are shown in red, purple, and green, respectively. Arrows indicate mutation locations: *, nonsense mutation; fs, frame-shift mutation. (from He et al., Development. 2004 Apr; 131(8):1663-77) .
LRP5 (low density lipoprotein receptor-related protein 5)
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Implicated in
Hyperparathyroid tumors, breast cancer Note According to Bjorklund's reports, the internally truncated human LRP5 receptor is strongly implicated in deregulated activation of the Wnt/beta-catenin signaling pathway in hyperparathyroid tumors and mammary gland tumorigenesis, and thus presents a potential target for therapeutic intervention.
The truncation version of LRP5 (LRP5∆666-809) missed the last 93 bp of exon 9, all 227 bp of exon 10, and the first 106 bp of exon 11. 
Oncogenesis
Other cancers
Note LRP5 is required for maintaining the basal lineage of mouse mammary tissue (Badders et al., 2009 ) and for mammary ductal stem cell activity and Wnt1-induced tumorigenesis (Lindvall et al., 2006) . LRP5 is a novel marker for disease progression in highgrade osteosarcoma (Hoang et al., 2004) . Dominant negative LRP5 showed inhibition of osteosarcoma tumorigenicity and metastasis in mouse model (Guo et al., 2008) .
Osteoporosis-pseudoglioma syndrome (OPPG)
Note Children with the autosomal recessive disorder osteoporosis pseudoglioma syndrome (OPPG) (Gong et al., 1996) have very low bone mass and are prone to developing fractures and deformation. In addition to the skeletal phenotype, many individuals with OPPG have eye involvement in the form of severe disruption of the ocular structure, called phthisis bulbi. (D111Y, G171R , A214T, A214V, A242T, and T253I) are located in the aminoterminal part of the gene, before the first epidermal growth factor-like domain, which is the same as for the G171V mutation that causes the high-bone-mass phenotype and most likely is disease-causing. Boyden et al. found that the expression of LRP5 V171 did not activate signaling in the absence of Wnt-1. The activation of the signaling pathway in response to Wnt-1 was the same with normal and mutant LRP5.They also tested the action of the endogenous antagonist of Wnt signaling, Dkk-1. Although Dkk-1 inhibited Wnt signaling in conjunction with wild-type LRP5, Dkk-1 inhibition of Wnt signaling was virtually abolished in cells expressing LRP5 V171 . These findings indicated that the mutation G171V, located in the first YWTD repeat of LRP5, results in increased Wnt signaling because of loss of Dkk antagonism to LRP5. However, Zhang et al. found that the third YWTD repeat (but not the first repeat domain) was required for DKK1-mediated antagonism. They found that the G171V mutation disrupted the interaction of LRP5 with Mesd, a chaperone protein for LRP5/6 that is required for transport of the co-receptors to cell surfaces, resulting in fewer LRP5 molecules on the cell surface. So they think that the G171V mutation may cause an increase in Wnt activity in osteoblasts by reducing the number of targets for paracrine DKK1 to antagonize without affecting the activity of autocrine Wnt. Ai et al. expressed seven different HBM-LRP5 missense mutations, including G171V, to delineate the mechanism by which they alter Wnt signaling. Each mutant receptor was able to reach the cell surface, albeit in differing amounts, and transduce exogenously supplied Wnt1 and Wnt3a signals. The affinities between the mutant forms of LRP5 and Mesd did not correlate with their abilities to reach the cell surface. All HBM mutant proteins had reduced physical interaction with and reduced inhibition by DKK1. These data suggest that HBM mutant proteins can transit to the cell surface in sufficient quantity to transduce Wnt signal and that the likely mechanism for the HBM mutations' physiologic effects is via reduced affinity to and inhibition by DKK1. Semenov further showed that LRP5 HBM mutant proteins exhibit reduced binding to a secreted bonespecific LRP5 antagonist, SOST, and consequently are more refractory to inhibition by SOST. Further, Bhat used structure-based mutation analysis to show the importance of LRP5 beta-propeller 1 in modulating Dkk1-mediated inhibition of Wnt signaling.
Familial exudative vitreoretinopathy (FEVR)
Note Familial exudative vitreoretinopathy (FEVR) is a welldefined inherited disorder of retinal vessel development (Benson, 1995) . It is reported to have a penetrance of 100%, but clinical features can be highly variable even within the same family. Severely affected patients may be legally blind during the first decade of life, whereas mildly affected individuals may not even be aware of symptoms and may receive a diagnosis only by use of fluorescein angiography. Cytogenetics As reported by Toomes et al., mutations in LRP5 within the EVR1 locus can cause FEVR, accounting for 15% of the patients and indicating that other unidentified FEVR genes may be a more significant cause of the disease than previously thought. Jiao et al. studied three consanguineous families of European descent in which autosomal recessive FEVR was diagnosed in multiple individuals. Sequencing of LRP5 showed, in all three families, homozygosity for mutation in LRP5: R570Q, R752G, and E1367K. Thus, mutations in the LRP5 gene can cause autosomal recessive as well as autosomal dominant FEVR. Qin et al. screened 56 unrelated patients with FEVR (31 familial and 25 simplex cases) for possible mutations in LRP5 and Frizzled 4 (FZD4). Six novel mutations in either LRP5 or FZD4 were identified in six familial cases. Four novel mutations in LRP5 and one known mutation in FZD4 were detected in three simplex cases, and two of these patients carried LRP5 (low density lipoprotein receptor-related protein 5) Zhong ZA, Williams BO Atlas Genet Cytogenet Oncol Haematol. 2011; 15(3) compound heterozygous mutations in LRP5. They also demonstrated that reduced bone density is a common feature in patients with FEVR who harbor LRP5 mutations.
Obesity
Note
Obesity is a growing health care problem and a risk factor for common diseases such as diabetes, heart disease, and hypertension. LRP5 is highly expressed in many tissues, including hepatocytes and pancreatic beta cells. Some evidence has shown that LRP5 can bind apolipoprotein E (apoE), which raises the possibility that LRP5 plays a role in the hepatic clearance of apoE-containing chylomicron remnants, a major plasma lipoprotein carrying dietderived cholesterol. Using LRP5 knock-out mice model, Fujino et al. showed that LRP5-deficient islets had a marked reduction in the levels of intracellular ATP and Ca 2+ in response to glucose, and thereby glucose-induced insulin secretion was decreased. The intracellular inositol 1,4,5-trisphosphate (IP3) production in response to glucose was also reduced in LRP5 -/-islets. The authors suggested that Wnt/LRP5 signaling contributes to the glucose-induced insulin secretion in the islets. Cytogenetics Guo et al. performed genotyping of 27 single nucleotide polymorphisms (SNPs), spaced 5 kb apart on average and covering the full transcript length of the LRP5 gene, using samples of 1873 Caucasian people from 405 nuclear families. They found that SNP4 (rs4988300) and SNP6 (rs634008), located in block 2 (intron 1), showed significant associations with obesity and BMI after Bonferroni correction (SNP4: p < 0.001 and p = 0.001, respectively; SNP6: p = 0.002 and 0.003, respectively). The common allele A for SNP4 and minor allele G for SNP6 were associated with an increased risk of obesity. Significant associations were also observed between the common haplotype A-G-G-G of block 2 and obesity, BMI, fat mass, and PFM, with global empirical values of p < 0.001, p < 0.001, p = 0.003 and p = 0.074, respectively. They concluded that intronic variants of the LRP5 gene are markedly associated with obesity, possibly due to the role of LRP5 in the Wnt signaling pathway or lipid metabolism.
